Generic Name and Formulations:
Cyproheptadine HCl 4mg; scored tabs.
Various generic manufacturers
Indications for Cyproheptadine:
Allergic and vasomotor rhinitis, conjunctivitis, urticaria, angioedema, reactions to blood. Adjunct in anaphylaxis. Cold urticaria. Dermatographism.
≥14yrs: initially 4mg 3 times daily; usual range 12–16mg/day; max 0.5mg/kg per day.
<2yrs: not recommended. 2–6yrs: 2mg 2–3 times per day; max 12mg daily. 7–14yrs: 4mg 2–3 times per day; max 16mg daily.
MAOIs. Glaucoma. GI or urinary obstruction. Elderly. Debilitated. Neonates. Premature infants. Nursing mothers.
Hyperthyroidism. Cardiovascular disease. Hypertension. Increased intraocular pressure. History of asthma. Pregnancy (Cat.B).
See Contraindications. Anticholinergic effects potentiated by MAOIs. Potentiates CNS depression with alcohol, other CNS depressants.
Drowsiness, dizziness, paradoxical excitement, anticholinergic effects, gastritis, hypotension, blood dyscrasias.
Formerly known under the brand name Periactin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC